poisar

Stocks · News reference

Deutsche Bank Adjusts Spyre Therapeutics Price Target to $141 From $123, Maintains Buy Rating

Fiscal.ai

Deutsche Bank has increased its price target for Spyre Therapeutics, Inc. while maintaining a Buy rating on the stock.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading